Key factors
symMRNA
exchUS
MCap39.52B
Beta1.601
EPS-12.3
Div date0000-00-00
Yesterday
symMRNA
exchUS
close106.56
50 Day MA99.50
200 Day MA101.43
52 Week High163.24
52 Week Low62.55
Target Price 129.49
Market Cap Mln39529
Share statistics
Shares Outstanding382.07M
Shares Float344.71M
Percent Institutions71.95
PercentInsiders9.602
SharesShort22.11M
Short Ratio5.38
Shares Short Prior Month24.07M
Short Percent7.689
Revenue TTM 6.848B
Revenue Per Share TTM 17.92
Quarterly Revenue Growth YOY -44.6
Gross Profit TTM 10.55B
EBITDA-3.61B
Diluted Eps TTM-12.3
Quarterly Earnings Growth YOY-85.1
earning
Operating Margin TTM 0.002
EPS Estimate Current Quarter -0.9
EPS Estimate Current Year -7.14
EPS Estimate Next Quarter -2.62
EPS Estimate Next Year -5.11
Earnings Share -12.3
Dividend
Dividend Date0000-00-00
Last Split Date 0000-00-00
business
Enterprise Value Ebitda -9.80
Enterprise Value Revenue4.765
Book Value /share 36.26
Price Book MRQ 2.854
Price Sales TTM 5.772
ProfitMargin -0.68
ReturnOnAssetsTTM -0.11
ReturnOnEquityTTM-0.28
Gic GroupPharmaceuticals, Biotechnology & Life Sciences
Gic IndustryBiotechnology
Gic Sector Health Care
Gic Sub Industry Biotechnology
IndustryBiotechnology
SectorHealthcare
ISIN US60770K1079
CIK 1682852
Code MRNA
CUSIP 60770K107
Employer Id Number 81-3467528
CountryISO US
Currency CodeUSD
Currency Name US Dollar
Exchange NASDAQ
Currency Symbol $
Type Common Stock
UpdatedAt 2024-03-15
Home Category Domestic
Fiscal Year End December
ForwardPE 32.46
Full Time Employees5600.0
IPODate 2018-12-07
International Domestic Domestic
MostRecent Quarter2023-12-31
Contact
NameModerna Inc
Address200 Technology Square, Cambridge, MA, United States, 02139
Country NameUSA
Phone617 714 6500
Web URLhttps://www.modernatx.com
Logo URL/img/logos/US/MRNA.png
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.